Roth Capital Analysts Give BioLineRx Ltd. (BLRX) a $3.00 Price Target

Roth Capital set a $3.00 price objective on BioLineRx Ltd. (NASDAQ:BLRX) in a report published on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a buy rating in a report on Saturday, June 3rd. Oppenheimer Holdings, Inc. assumed coverage on shares of BioLineRx in a report on Friday, August 4th. They set an outperform rating and a $3.00 target price for the company. Maxim Group raised shares of BioLineRx from a hold rating to a buy rating and lifted their target price for the company from $1.00 to $3.00 in a report on Thursday, May 18th. Zacks Investment Research raised shares of BioLineRx from a hold rating to a buy rating and set a $1.00 target price for the company in a report on Friday, April 21st. Finally, ValuEngine raised shares of BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioLineRx has a consensus rating of Buy and an average target price of $2.59.

BioLineRx (BLRX) opened at 1.17 on Wednesday. The company’s market capitalization is $111.87 million. The firm has a 50 day moving average of $0.96 and a 200-day moving average of $0.97. BioLineRx has a 52-week low of $0.80 and a 52-week high of $1.42.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Equities analysts expect that BioLineRx will post ($0.24) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Roth Capital Analysts Give BioLineRx Ltd. (BLRX) a $3.00 Price Target” was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/13/roth-capital-analysts-give-biolinerx-ltd-blrx-a-3-00-price-target.html.

Large investors have recently modified their holdings of the company. Citadel Advisors LLC raised its stake in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of BioLineRx during the first quarter valued at approximately $126,000. Benchmark Capital Advisors raised its stake in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the last quarter. KCG Holdings Inc. raised its stake in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the last quarter. Finally, Sabby Management LLC bought a new stake in shares of BioLineRx during the first quarter valued at approximately $3,018,000. 34.91% of the stock is owned by institutional investors.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply